<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>22397982</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Grau-Amorós, Jorge</dc:author>
<dc:author>Urrutia, Agustín</dc:author>
<dc:author>Formiga, Francesc</dc:author>
<dc:author>Aramburu, Oscar</dc:author>
<dc:author>Trullàs, Joan Carles</dc:author>
<dc:author>Recio-Iglesias, Jesús</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVE To assess the prognosis and etiology of anemia in heart failure (HF). PATIENTS AND METHODS Prospective multicenter cohort of HF after one year of hospitalization. RESULTS A total of 57 (27%) of the 211 patients died and 115 (67.8%) were readmitted. Mortality was higher in the group with anemia (31.8%) without statistical significance (P=.09), except for refractory HF mortality (P=.013). Predictors of HF mortality included Barthel index (hazard ratio [HR] 0.97, CI 95% 0.96 to 0.98) and serum creatinine at discharge (HR 2.28, 95% CI 1.51 to 3.45). For reentry, the Charlson index (OR 1.16, CI 95% 0.98 to 1.38), treatment with calcium channel blockers (OR 0.29, 95% CI 0.1 to 0.84) and not being treated with digoxin (OR 2.33, CI 95% 1.09 to 4.97), the latter with the greatest influence on readmission for HF (OR 3.07, CI 95% 1.39 to 6.79), along with not being a HF debut (OR 2.8, CI 95% 1.45 to 5.39). CONCLUSIONS Anemia is an increased risk of mortality due to refractory HF, but not for readmission within the first year after an acute event.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2012 May 26 </dc:date>
<dc:title xml:lang="es">Anemia en la insuficiencia cardiaca: su utilidad como marcador de pronóstico o de comorbilidad: estudio GESAIC-2.</dc:title>
<dc:title xml:lang="en">[Anemia in heart failure: its usefulness as prognosis or comorbidity marker: GESAIC-2 study].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
